Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akari Therapeutics PlcAKTX · Entity 7692 | CFO | March 20, 2025 | March 24, 2025 |
| Aspira Women's Health Inc.AWH · Entity 7871 | Chief Financial Officer | May 03, 2024 | June 14, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akari Therapeutics Plc
Report date March 20, 2025 · Filed March 24, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.50 · Expires 2035-03-20 | Direct | 300,000 |
Reported balance
After 2025-03-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-03-20 · Grant · Acquired 300,000 · Balance 300,000 F2: The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. The stock option shall vest over four years from the grant date with 25% vesting on the 12 month anniversary of the grant date, and the remainder vesting ratably on a monthly basis over the then remaining 36 months from the grant date, such that it will be fully vested on the fourth anniversary of the grant date. The stock option award is subject to continued service with the Issuer. F1: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.50 · Expires 2035-03-20 | Direct | 200,000 |
Reported balance
After 2025-03-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-03-20 · Grant · Acquired 200,000 · Balance 200,000 F3: The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. The stock options shall vest upon achievement of at least one of the following performance criteria: either (a) closing of a qualified financing of at least $15,000,000 in gross proceeds on or before December 31, 2025, or (b) closing of an antibody drug conjugate ("ADC") focused license transaction, with a minimum upfront payment of $10,000,000 on or before December 31, 2025. If neither of these criteria are met by December 31, 2025 the performance-based option will expire. The stock option award is subject to continued service with the Issuer. F1: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. |
| American Depositary Shares representing Ordinary SharesSEC Table I · non-derivative | Direct | 200 |
Reported balance
Holding disclosure · report date 2025-03-20 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 200 F1: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer.
F2: The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. The stock option shall vest over four years from the grant date with 25% vesting on the 12 month anniversary of the grant date, and the remainder vesting ratably on a monthly basis over the then remaining 36 months from the grant date, such that it will be fully vested on the fourth anniversary of the grant date. The stock option award is subject to continued service with the Issuer.
F3: The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. The stock options shall vest upon achievement of at least one of the following performance criteria: either (a) closing of a qualified financing of at least $15,000,000 in gross proceeds on or before December 31, 2025, or (b) closing of an antibody drug conjugate ("ADC") focused license transaction, with a minimum upfront payment of $10,000,000 on or before December 31, 2025. If neither of these criteria are met by December 31, 2025 the performance-based option will expire. The stock option award is subject to continued service with the Issuer.
Aspira Women's Health Inc.
Report date May 03, 2024 · Filed June 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| EMPLOYEE STOCK OPTION (RIGHT TO BUY)SEC Table II · derivative / convertible security · Conversion / exercise price $3.20 · Expires 2033-12-05 | Direct | 6,667 |
Reported balance
After 2024-05-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-05-03 · Grant · Acquired 6,667 · Balance 6,667 F1: An option to purchase 6,667 shares of common stock was granted to the reporting person on 12/5/2023, subject to the satisfaction of certain performance conditions. On 5/3/2024, the performance conditions were deemed to have been met. The 6,667 shares will vest on 6/15/2024. |
Filing footnotes · ownership attribution and instrument terms
F1: An option to purchase 6,667 shares of common stock was granted to the reporting person on 12/5/2023, subject to the satisfaction of certain performance conditions. On 5/3/2024, the performance conditions were deemed to have been met. The 6,667 shares will vest on 6/15/2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 20, 2025 Filed Mar 24, 2025 21:00 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0000950170-25-043934 · ownership.xml · derivative · entry 3 Hombeck Torsten · CIK 0001983682 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: American Depositary Shares representing Ordinary Shares · 200,000 shares Expires 2035-03-20 F3 · derivative.exercise_date: The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. The stock options shall vest upon achievement of at least one of the following performance criteria: either (a) closing of a qualified financing of at least $15,000,000 in gross proceeds on or before December 31, 2025, or (b) closing of an antibody drug conjugate ("ADC") focused license transaction, with a minimum upfront payment of $10,000,000 on or before December 31, 2025. If neither of these criteria are met by December 31, 2025 the performance-based option will expire. The stock option award is subject to continued service with the Issuer. F1 · derivative.underlying: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. Read SEC document |
| March 20, 2025 Filed Mar 24, 2025 21:00 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0000950170-25-043934 · ownership.xml · derivative · entry 2 Hombeck Torsten · CIK 0001983682 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: American Depositary Shares representing Ordinary Shares · 300,000 shares Expires 2035-03-20 F2 · derivative.exercise_date: The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. The stock option shall vest over four years from the grant date with 25% vesting on the 12 month anniversary of the grant date, and the remainder vesting ratably on a monthly basis over the then remaining 36 months from the grant date, such that it will be fully vested on the fourth anniversary of the grant date. The stock option award is subject to continued service with the Issuer. F1 · derivative.underlying: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. Read SEC document |
| January 10, 2025 Filed Jan 13, 2025 13:05 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantAmerican Depository Shares representing Ordinary Shares | 200 | $1.22 | $244.00 |
DisclosureSEC source: 0000950170-25-004577 · ownership.xml · nonDerivative · entry 1 Hombeck Torsten · CIK 0001983682 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200 F1 · security: Each American Depository Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. F2 · kind: On January 10, 2025, the Reporting Person acquired 200 ADS at purchase price of $1.22 per ADS. F2 · price: On January 10, 2025, the Reporting Person acquired 200 ADS at purchase price of $1.22 per ADS. Read SEC document |
| May 13, 2024 Filed May 14, 2024 23:54 UTC | Aspira Women's Health Inc. AWH · Entity 7871 | GrantEMPLOYEE STOCK OPTION (RIGHT TO BUY) · Derivative | 22,000 | $0.00 Strike: $2.88 | $0.00 |
DisclosureSEC source: 0001983682-24-000002 · primary_doc.xml · derivative · entry 1 Hombeck Torsten · CIK 0001983682 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: COMMON STOCK · 22,000 shares Expires 2034-05-13 F1 · derivative.exercise_date: The employee stock option will vest in equal monthly installments over four years beginning June 13, 2024. Read SEC document |
| May 03, 2024 Filed Jun 14, 2024 21:17 UTC | Aspira Women's Health Inc. AWH · Entity 7871 | GrantEMPLOYEE STOCK OPTION (RIGHT TO BUY) · Derivative | 6,667 | $3.20 Strike: $3.20 | $21,334.40 |
DisclosureSEC source: 0001983682-24-000003 · primary_doc.xml · derivative · entry 1 Hombeck Torsten · CIK 0001983682 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,667 Underlying: Common Stock · 6,667 shares Expires 2033-12-05 F1 · derivative.exercise_date: An option to purchase 6,667 shares of common stock was granted to the reporting person on 12/5/2023, subject to the satisfaction of certain performance conditions. On 5/3/2024, the performance conditions were deemed to have been met. The 6,667 shares will vest on 6/15/2024. Read SEC document |
| February 14, 2024 Filed Feb 15, 2024 01:17 UTC | Aspira Women's Health Inc. AWH · Entity 7871 | GrantEmployee stock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.87 | $0.00 |
DisclosureSEC source: 0001983682-24-000001 · primary_doc.xml · derivative · entry 1 Hombeck Torsten · CIK 0001983682 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common stock · 20,000 shares Expires 2034-02-14 F1 · derivative.exercise_date: The employee stock option will vest in three equal annual amounts beginning February 14, 2025. Read SEC document |
| November 17, 2023 Filed Nov 21, 2023 00:37 UTC | Aspira Women's Health Inc. awh · Entity 7871 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001983682-23-000005 · primary_doc.xml · nonDerivative · entry 1 Hombeck Torsten · CIK 0001983682 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,000 F1 · shares: The shares of common stock represent restricted stock units with contingent right to receive one share of common stock. The restricted stock units vest 50% on March 31, 2024 and 50% on June 30, 2024. Read SEC document |
| September 08, 2023 Filed Sep 12, 2023 22:37 UTC | Aspira Women's Health Inc. AWH · Entity 7871 | PurchaseCommon Stock | 2,246 | $4.30 | $9,657.80 |
DisclosureSEC source: 0001983682-23-000004 · primary_doc.xml · nonDerivative · entry 1 Hombeck Torsten · CIK 0001983682 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Read SEC document |
| July 25, 2023 Filed Jul 26, 2023 20:39 UTC | Aspira Women's Health Inc. AWH · Entity 7871 | GrantEmployee Stock Option (Right to Buy) · Derivative | 13,334 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001983682-23-000003 · primary_doc.xml · derivative · entry 1 Hombeck Torsten · CIK 0001983682 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,334 Underlying: Common Stock · 13,334 shares Expires 2033-07-25 F1 · derivative.exercise_date: The employee stock option will vest in three equal annual amounts beginning June 15, 2024. Read SEC document |
| July 24, 2023 Filed Jul 24, 2023 22:53 UTC | Aspira Women's Health Inc. AWH · Entity 7871 | PurchaseCommon stock | 754 | $3.98 | $3,000.92 |
DisclosureSEC source: 0001983682-23-000002 · primary_doc.xml · nonDerivative · entry 1 Hombeck Torsten · CIK 0001983682 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 754 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.